IntelliPharmaCeutics International (IPCI)
News
| May 29 | $IPCI Husband-and-wife team's winning formula @ CNN (Video) http://stks.co/410Y by IPCI |
| May 01 | $IPCI Intellipharmaceutics Meets a 2012 Goal for Abuse-Deterrent Oxycodone http://stks.co/3bVF by IPCI |
| May 01 | Intellipharmaceutics meets 2012 goal for abuse-deterrent Oxycodone |
| May 01 | Intellipharmaceutics Meets a 2012 Goal for Abuse-Deterrent Oxycodone GlobeNewswire |
| Apr 16 | Intellipharmaceutics Announces First Quarter 2012 Results ($IPCI) http://stks.co/3MZm by IPCI |
| Apr 12 | Intellipharmaceutics Announces First Quarter 2012 Results GlobeNewswire |
| Mar 29 | $IPCI FDA Releases Draft Guidance on dexmethylphenidate hydrochloride http://stks.co/38Wi by IPCI |
| Mar 27 | Intellipharmaceutics Announces Webcast of Presentation at the 11th Annual Needham Healthcare Conference - $IPCI http://stks.co/36Cb by IPCI |
| Mar 27 | Intellipharmaceutics Announces Webcast of Presentation at the 11th Annual Needham Hea... |
| Mar 26 | $IPCI Intellipharmaceutics Appoints VP of Business Development @ HealthCare Distributor http://stks.co/34xP by IPCI |
| Mar 15 | Intellipharmaceutics Closes US$5,000,000 Registered Direct Offering of Common Shares GlobeNewswire |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Drug Delivery & Accessories
IntelliPharmaCeutics is a Canadian specialty pharmaceutical company, operating internationally and primarily engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Dexmethylphenidate XR is a generic version of the marketed drug Focalin XR, which is partnered with Par Pharmaceutical and is currently the subject of an Abbreviated New Drug Application filing with the U.S. Food and Drug Administration .
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). IntelliPharmaCeutics International is down 29.02% over the last year vs S&P 500 Total Return up 2.32%, Acura Pharmaceuticals down 39.67%, and Elan Corporation up 54.10%.
- IPCI Total Returns
- ^SPXTR Total Returns
- ACUR Total Returns
- ELN Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these IPCI related companies
Pro Strategies Featuring IPCI
Did IntelliPharmaCeutics International make it into our Pro Portfolio Strategies?
IPCI Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other IPCI Resources
- Wiki Page
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IPCI | 2.96 | +0.00 | +0.00% | 47.09M |
| IPCC | 54.03 | -0.58 | -1.06% | 644.40M |
| IPAS | 2.35 | -0.03 | -1.26% | 141.06M |
| IPAR | 15.45 | -0.29 | -1.84% | 481.01M |
| IP | 29.32 | -0.60 | -2.01% | 13.08B |
| IOT | 1.67 | -0.06 | -3.47% | 6.964M |
| IOSP | 26.45 | -0.86 | -3.15% | 630.04M |
| IHS | 100.17 | -1.53 | -1.50% | 6.629B |
| IHI | 63.13 | -1.02 | -1.59% | |
| IHG | 22.26 | -0.53 | -2.33% | 6.634B |
